Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 4/20 | 0.33 |
| ▸ | SI | P14410 | 4/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579718 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL12324839 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2041954 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL12289253 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL2041957 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL24538673 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL18023809 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL15127516 | 1.00 | TK1 (0.37) | TK1CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3169389 | 0.88 | MGAM (0.37) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL10262996 | 0.88 | MGAM (0.37) | CHRM5CHRM1CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | TK1 31/4885CHRM5 4849/4885CHRM1 4866/4885 |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | TK1 29/4885CHRM5 4709/4885CHRM1 4648/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | TK1 198/4885CHRM5 2828/4885CHRM1 2816/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | TK1 31/4885CHRM5 4849/4885CHRM1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.